Industry / China
WuXi Set For Growth
December 2007 | Company Finance AlertSome market observers question whether Chinese outsourcing firm WuXi PharmaTech - which can be involved in every stage of the drug development process, from manufacturing to preparing regulatory submissions for clients - can maintain the stellar performance displayed in recent times. But because Western multinationals will continue to cut costs in an increasingly hostile operating environment, BMI is predicting significantly more business and higher profits for the Shanghai-based
Sorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Asia Pacific Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Asia Pacific Pharma & Healthcare Insight please click on the trial link below.
